Travere Therapeutics (TVTX) Gross Profit (2014 - 2026)

Travere Therapeutics has reported Gross Profit for 13 years, with the latest figure at $102.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 47.72% year-over-year to $102.4 million; the trailing twelve-month figure through Mar 2026 stood at -$100.6 million (down 139.46% YoY), and the FY2025 full-year result was -$1.0 million, down 100.46% from the prior year.
• Gross Profit for Q1 2026 stood at $102.4 million, up from -$354.3 million in the prior quarter.
• The five-year high for Gross Profit was $112.9 million in Q2 2025, with the low at -$354.3 million in Q4 2025.
• Historically, Gross Profit has averaged $25.4 million across 5 years, with a median of $38.4 million in 2025.
• Annual changes were most pronounced in 2022 — Gross Profit jumped 118.11% — and 2025, when it tumbled 590.48%.
• Travere Therapeutics' Gross Profit stood at $28.5 million in 2022, then soared by 42.23% to $40.5 million in 2023, then jumped by 78.38% to $72.2 million in 2024, then plunged by 590.48% to -$354.3 million in 2025, then soared by 128.9% to $102.4 million in 2026.
• The last three Gross Profit figures came in at $102.4 million (Q1 2026), -$354.3 million (Q4 2025), and $38.4 million (Q3 2025), per Business Quant data.